Penumbra (PEN) CEO-linked trust donates 77,000 shares in charitable stock gift
A trust linked to Penumbra Inc. (PEN) CEO Adam Elsesser has made a charitable donation of 77,000 shares of common stock to a Massachusetts school. This transaction was a non-cash gift, not an open-market sale, with a stated price of zero per share. After the donation, the trust's indirect holdings for Elsesser amount to 683,042 shares.
(PEN) Movement as an Input in Quant Signal Sets
This article provides a quantitative analysis of Penumbra Inc. (NYSE: PEN), highlighting a neutral near and mid-term outlook that could moderate a long-term positive bias. It details an exceptional 28.3:1 risk-reward setup targeting an 8.2% gain against 0.3% risk, driven by a mid-channel oscillation pattern. The analysis includes AI-generated trading strategies—position trading, momentum breakout, and risk hedging—along with multi-timeframe signal analysis for various holding periods.
120,815 Shares in Penumbra, Inc. $PEN Purchased by Stephens Investment Management Group LLC
Stephens Investment Management Group LLC has acquired a new position in Penumbra, Inc. (NYSE:PEN), purchasing 120,815 shares valued at approximately $37.56 million. This makes up about 0.31% of Penumbra, a global healthcare company specializing in neurovascular and peripheral vascular medical devices. Despite missing Q1 earnings expectations, Penumbra's revenue increased by 15.6% year-over-year, and analysts generally maintain a "Hold" rating on the stock.
Thrivent Financial for Lutherans Sells 72,330 Shares of Penumbra, Inc. $PEN
Thrivent Financial for Lutherans significantly reduced its stake in Penumbra, Inc. (NYSE:PEN) by 19.7% in the fourth quarter, selling 72,330 shares and retaining 294,732 shares valued at approximately $91.6 million. This move comes amid continued insider selling from Penumbra executives and a cautious "Hold" rating from Wall Street analysts, who set a consensus price target of $361.33. Penumbra also missed its quarterly EPS estimates, despite a 15.6% year-over-year revenue increase.
Penumbra, Inc. (NYSE:PEN) Receives Consensus Rating of "Hold" from Analysts
Penumbra, Inc. (NYSE:PEN) has received a consensus "Hold" rating from analysts, with 14 out of 17 analysts recommending a hold and three a buy, setting an average 1-year price target of $361.33. The company recently missed EPS estimates but slightly exceeded revenue expectations, with year-over-year revenue growth of 15.6%. Notable insider selling occurred, including transactions by the CFO and a director, while institutional ownership remains high at 88.88%.
Penumbra, Inc. (PEN) Stock Analysis: Navigating a 12.76% Upside in the Medical Devices Sector
Penumbra, Inc. (PEN) is a U.S.-based medical devices company with a market capitalization of $12.67 billion, specializing in products like the Indigo System and Lightning Bolt 7. Despite a recent modest price dip, analysts project a potential 12.76% upside with an average target price of $363.36, driven by strong revenue growth and anticipated future earnings. The company reinvests heavily into growth, does not offer dividends, and technical indicators suggest a possible buying opportunity as the stock is in oversold territory with an RSI of 20.85.
Penumbra, Inc. Reports Third Quarter 2025 Financial Results
Penumbra, Inc. (PEN) has released its financial results for the third quarter of 2025. This information was disseminated via a press release and alerted to Quantisnow Plus members shortly after publication. Quantisnow, a market data and news platform, provided real-time alerts on this and other market-moving events for retail investors.
Penumbra posts $32.6M profit as Boston Scientific deal halts outlook
Penumbra Inc. reported Q1 2026 revenue of $374.8 million, a 15.6% year-over-year increase, and a net income of $32.6 million. The company will not provide full-year 2026 guidance or host an earnings call due to its pending acquisition by Boston Scientific. This announcement highlights consistent double-digit revenue growth and profitability while detailing financial figures across various segments and operating expenses.
Penumbra Shareholders Approve Merger with Boston Scientific
Penumbra shareholders approved the merger with Boston Scientific on May 6, 2026, making Penumbra a wholly owned subsidiary of Boston Scientific. The deal's completion is now pending regulatory and other closing conditions. Spark, TipRanks' AI Analyst, rates PEN as Neutral, citing strong financial performance offset by an expensive valuation and a soft technical setup.
Penumbra shareholders approve merger with Boston Scientific
Penumbra, Inc. shareholders have approved the company's merger with Boston Scientific Corporation, following a special meeting. The approval clears a significant condition for the merger, which will see Penumbra become a wholly owned subsidiary of Boston Scientific. The completion of the merger is contingent upon further regulatory approvals, including antitrust clearances.
Penumbra (NYSE: PEN) investors back merger, await antitrust approvals
Penumbra, Inc. stockholders approved all three merger-related proposals at a special meeting on May 6, 2026, satisfying a major condition for the merger agreement. Despite strong shareholder support, the acquisition's completion is still pending regulatory approvals, including the Hart-Scott-Rodino waiting period and other non-U.S. antitrust clearances. These remaining conditions will dictate the final timing and feasibility of the merger.
Penumbra (NYSE: PEN) shareholders approve Merger Proposal; closing conditions remain
Penumbra, Inc. shareholders approved a Merger Proposal at a special meeting held on May 6, 2026. The approval satisfies a key condition for the merger with Boston Scientific Corporation, however, the consummation of the merger remains subject to other closing conditions, including Hart-Scott-Rodino clearance and other required antitrust and foreign investment approvals. A significant majority of the shares voted for the Merger Proposal, along with advisory compensation and adjournment proposals.
Press Release: Penumbra, Inc. Reports First Quarter 2026 Financial Results
This article reports that Penumbra, Inc. has released its first-quarter 2026 financial results. It briefly mentions that Unity Software's fourth-quarter revenue increased 35% year-over-year to $609 million, though this seems to be a misplaced detail. The main focus is on Penumbra's financial report for Q1 2026.
Penumbra (NYSE: PEN) posts $374.8M Q1 2026 revenue as Boston Scientific deal looms
Penumbra (NYSE: PEN) reported Q1 2026 revenue of $374.8 million, a 15.6% increase year-over-year, driven by strong growth in both thrombectomy and embolization businesses. Despite improved gross profit margins, net income decreased to $32.6 million due to higher operating expenses, including $9.4 million related to its pending acquisition by Boston Scientific Corporation. Consequently, Penumbra is not providing full-year 2026 financial guidance or hosting a conference call.
Penumbra Inc. Profit Drops In Q1
Penumbra Inc. reported a significant drop in profit for the first quarter, with earnings falling to $32.58 million, or $0.82 per share, compared to $39.22 million, or $1.00 per share, in the same period last year. Despite the profit decline, the company's revenue increased by 15.6% to $374.75 million from $324.14 million a year ago.
Earnings Flash (PEN) Penumbra, Inc. Reports Q1 Revenue $374.8M, vs. FactSet Est of $371.3M
Penumbra, Inc. (PEN) announced its Q1 revenue reached $374.8 million, exceeding FactSet's estimate of $371.3 million. The company, which specializes in thrombectomy devices for various medical conditions, also reported recent positive trial results for its Storm-PE study, showing improved functional outcomes with thrombectomy plus anticoagulation. Penumbra's stock closed at $324.19, reflecting recent analyst coverage and other company news.
Penumbra: Q1 Earnings Snapshot
Penumbra Inc. reported first-quarter net income of $32.6 million, or 82 cents per share, falling short of Wall Street's expectations of $1.11 per share. The medical device maker generated $374.8 million in revenue during the period. This earnings snapshot was compiled using data from Zacks Investment Research.
Penumbra, Inc. Reports First Quarter 2026 Financial Results
Penumbra, Inc. reported its first-quarter 2026 financial results, with total revenue reaching $374.8 million, a 15.6% increase year-over-year. The company's thrombectomy revenue grew 12.1% to $253.9 million, and embolization/access revenue increased by 23.8% to $120.8 million. Due to its pending acquisition by Boston Scientific Corporation, Penumbra will not provide full-year financial guidance or host a conference call.
Penumbra posts $32.6M profit as Boston Scientific deal halts outlook
Penumbra (NYSE: PEN) reported strong Q1 2026 financial results with revenue increasing 15.6% year-over-year to $374.8 million and a net income of $32.6 million. However, the company will not provide full-year guidance or host an earnings call due to its pending acquisition by Boston Scientific (NYSE: BSX). The acquisition introduces $9.4 million in related expenses but sets the stage for integration into Boston Scientific's growing portfolio.
Hussman Strategic Advisors Inc. Sells 8,400 Shares of Penumbra, Inc. $PEN
Hussman Strategic Advisors Inc. significantly reduced its stake in Penumbra, Inc. by selling 8,400 shares, retaining 4,200 shares valued at $1.306 million. Despite a 22.2% revenue increase, Penumbra missed its EPS estimates in the last quarter. The stock has a "Hold" rating from analysts with an average price target of $364.60, and institutional ownership remains high at 88.88%.
Penumbra earnings in focus as Boston Scientific deal looms
Penumbra Inc. is set to release its first-quarter earnings as it navigates a $14.5 billion acquisition by Boston Scientific. Analysts expect year-over-year increases in EPS and revenue but also a sequential decline, raising questions about potential headwinds. Investors will be closely watching for explanations regarding the sequential revenue dip, updates on the STORM-PE trial's impact, and any signals regarding the timeline and regulatory status of the Boston Scientific acquisition.
Vanguard Group Inc. Cuts Stock Position in Penumbra, Inc. $PEN
Vanguard Group Inc. reduced its stake in Penumbra, Inc. by 1.7% in Q4 2025, selling over 64,000 shares and now holding approximately 9.63% of the company's stock valued at $1.17 billion. This comes as Penumbra reported a significant EPS miss for the quarter despite revenue exceeding expectations. Analysts currently rate Penumbra as a "Hold" with an average price target of $364.60, while corporate insiders have also been reducing their holdings.
Penumbra, Inc. (NYSE:PEN) Sees Large Drop in Short Interest
Penumbra, Inc. (NYSE:PEN) experienced a significant 17.7% decline in short interest during April, reaching 2,007,168 shares by April 15. This represents approximately 5.3% of the company's stock and a short-interest ratio of 4.2 days. Despite missing EPS estimates in its latest quarter, Penumbra's revenue increased by 22.2% year-over-year, and analysts largely maintain a "Hold" rating with an average price target of $364.60.
Vanguard Capital Management (NYSE: PEN) holds 1.99M shares, 5.07% stake
Vanguard Capital Management has reported a beneficial ownership of 1,990,629 shares in Penumbra Inc. (NYSE: PEN), which represents a 5.07% stake. This information is disclosed in a Schedule 13G SEC filing, indicating Vanguard's passive investment intentions. The filing details Vanguard's sole dispositive power over all 1.99 million shares and sole voting power over 296,141 shares, signed by Ashley Grim.
Penumbra (NYSE: PEN) outlines 2026 meeting and $14.5B Boston Scientific sale
Penumbra has announced its 2026 annual stockholder meeting for June 18, 2026, where shareholders will vote on director elections, auditor ratification, and executive compensation. A separate special meeting will address the proposed $14.5 billion acquisition by Boston Scientific Corporation, valuing Penumbra shares at $374 each, with consideration split between cash and Boston Scientific stock. The proxy statement details the financial terms of the merger and outlines the company's executive compensation philosophy, which emphasizes base salary and long-term equity awards.
Penumbra Inc SEC Filing
Penumbra Inc. (PEN) filed an ARS form with the SEC on April 29, 2026. This filing is available as a PDF document and has a low impact and neutral sentiment. The article also provides an overview of Penumbra, including its market capitalization, recent news, and other SEC filings.
Teacher Retirement System of Texas Reduces Stake in Penumbra, Inc. $PEN
The Teacher Retirement System of Texas decreased its holdings in Penumbra, Inc. by 31% in the fourth quarter of 2025, selling 3,704 shares and ending with 8,245 shares valued at $2.563 million. This reduction occurred despite Penumbra's 22.2% year-over-year revenue increase in Q4, as the company missed EPS expectations. Analysts currently have a consensus "Hold" rating for Penumbra with a target price of $364.60, and corporate insiders have also recently sold shares.
A Look At Penumbra (PEN) Valuation After Positive STORM PE Trial Outcomes
Penumbra (PEN) shares are in focus after positive 3-month outcomes from its STORM-PE trial, which showed computer-assisted vacuum thrombectomy (CAVT) outperformed anticoagulation alone for pulmonary embolism. Despite a recent decline, the stock has shown positive year-to-date and long-term returns. The company is considered potentially undervalued by some analysts at $365.79 due to clinical data and market expansion, although its high P/E ratio suggests a premium valuation.
Why (PEN) Price Action Is Critical for Tactical Trading
This article analyzes Penumbra Inc. (NYSE: PEN) stock, identifying neutral near and mid-term readings but a strong long-term positive bias. It highlights a 32.0:1 risk-reward short setup and provides institutional trading strategies for various risk profiles, including position, momentum breakout, and risk hedging. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
How STORM-PE Thrombectomy Results and Lightning Flash Data Will Impact Penumbra (PEN) Investors
Penumbra recently announced positive 90-day results from its STORM-PE trial, showing improved functional outcomes and comparable safety for its Lightning Flash CAVT system in treating pulmonary embolism. These results strengthen Penumbra's investment case, especially regarding broader adoption of its thrombectomy technology. However, investors also need to consider the pending acquisition by Boston Scientific, which shifts focus to closing conditions and integration risks, alongside competitive and pricing pressures.
How STORM-PE Thrombectomy Results and Lightning Flash Data Will Impact Penumbra (PEN) Investors
Penumbra, Inc. recently announced positive 90-day results from its STORM-PE randomized trial, indicating that its Lightning Flash CAVT system significantly improves functional outcomes for high-risk pulmonary embolism patients compared to anticoagulation alone. These results bolster Penumbra's investment narrative for minimally invasive clot removal and may influence its stock valuation. However, investors should also consider the impact of Boston Scientific's planned acquisition and ongoing competition in the thrombectomy market.
M&T Bank Corp Grows Position in Penumbra, Inc. $PEN
M&T Bank Corp significantly increased its stake in Penumbra, Inc. (NYSE:PEN) by 4,733.1% in Q4, acquiring an additional 38,149 shares to total 38,955 shares, valued at $12.1 million. Despite a recent earnings miss, Penumbra's revenue beat expectations and increased 22.2% year-over-year, leading to a consensus "Hold" rating from analysts with an average target price of $364.60. However, company insiders have been selling shares, further contributing to a mixed outlook for the medical device company.
Penumbra, Inc. (PEN) Stock Analysis: A Healthcare Contender With 10% Upside Potential
Penumbra, Inc. (NYSE: PEN) is a medical device company with a market capitalization of $13.03 billion, specializing in thrombectomy and embolization products. Analysts predict a 10.13% upside potential, targeting an average price of $365.79, supported by a 22.10% revenue growth rate and $92.69 million in free cash flow. While technical indicators suggest the stock might be overbought in the short term, the company's innovation and reinvestment strategy position it for long-term growth in the healthcare sector.
Penumbra Inc stock (US70975L1070): Why Google Discover changes matter more now
Google's 2026 Discover Core Update is revolutionizing how investors access news on companies like Penumbra Inc, delivering personalized medical technology insights directly to mobile feeds. This update prioritizes proactive, mobile-first content delivery based on user activity, making it crucial for investors tracking innovation in neurovascular and peripheral vascular devices. For Penumbra Inc stock, this means faster access to critical updates on product launches, clinical data, and market dynamics, offering a competitive advantage for informed investment decisions.
Q3 2025 Penumbra Inc Earnings Call Transcript
This article provides the edited transcript of Penumbra Inc's Q3 2025 earnings call, held on November 5, 2025. It highlights key positive developments such as strong revenue growth, gross margin expansion, and successful product launches, as well as challenges including modest international growth, a decline in the US neurovascular business, and increased operating expenses. The company also raised its revenue guidance for the year despite some anticipated Q4 deceleration.
Board backs Boston Scientific acquisition of Penumbra (PEN); Special Meeting May 6, 2026
Penumbra's Board of Directors unanimously recommends shareholders vote FOR the proposed merger with Boston Scientific Corporation. A special meeting is scheduled for May 6, 2026, for shareholders to vote on the merger, and all necessary proxy materials have been distributed. Shareholders are urged to vote promptly, as failing to vote has the same effect as voting against the merger.
Penumbra, Inc. (NYSE:PEN) Receives Average Rating of "Hold" from Brokerages
Penumbra, Inc. (NYSE:PEN) has received an average "Hold" rating from eighteen brokerages, with fourteen analysts assigning a hold and four a buy rating. The average 12-month price target is $361.69. The company recently reported a quarterly EPS miss of -$0.37 against an expected $1.12, though revenue of $385.39 million beat estimates and grew 22.2% year-over-year.
Did STORM-PE’s Strong Functional Outcomes Just Shift Penumbra's (PEN) Investment Narrative?
Penumbra, Inc. (PEN) recently released 90-day results from its STORM-PE clinical trial, demonstrating that its computer-assisted vacuum thrombectomy (CAVT) technology, combined with anticoagulation, yielded superior functional outcomes and comparable safety for patients with intermediate-high risk pulmonary embolism compared to anticoagulation alone. These findings, particularly the improved six-minute walk distance, could significantly influence future treatment guidelines and boost the clinical adoption of Penumbra's CAVT technology, potentially reshaping the company's investment narrative by reinforcing its market position and growth prospects. However, investors should consider the potential for slower-than-anticipated adoption by hospitals, payers, or guideline committees, which could temper the commercial impact of these positive trial results.
Understanding Momentum Shifts in (PEN)
This article analyzes Penumbra Inc. (NYSE: PEN), indicating a neutral near and mid-term outlook while maintaining a positive long-term bias. It highlights resistance testing and presents three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, each with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strength, support, and resistance levels for various trading horizons.
Did STORM-PE’s Strong Functional Outcomes Just Shift Penumbra's (PEN) Investment Narrative?
Penumbra, Inc. recently released 90-day results from its STORM-PE trial, indicating that computer-assisted vacuum thrombectomy (CAVT) combined with anticoagulation significantly improved functional outcomes and maintained comparable safety for patients with intermediate-high risk pulmonary embolism compared to anticoagulation alone. These Level 1 evidence findings, especially improved walking distance and functional recovery, could bolster the clinical adoption of Penumbra's CAVT technology and influence future treatment guidelines, thereby potentially reshaping the company's investment narrative. While the trial supports a near-term catalyst for CAVT adoption, investors should also consider the risk of slower-than-expected adoption by hospitals, payers, or guideline committees, despite strong revenue and earnings forecasts for Penumbra.
Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A
Boston Scientific (NYSE: BSX) is set to acquire Penumbra (NYSE: PEN) for an estimated $14.9 billion, a strategic move to re-enter and dominate the stroke treatment market, which it exited previously. This acquisition is seen as one of the largest MedTech deals of the decade, signifying a significant consolidation trend in the healthcare sector. The deal is expected to create a comprehensive "Stroke Management Suite" leveraging Penumbra's advanced technologies and Boston Scientific's global distribution, though it faces integration challenges and regulatory scrutiny.
Penumbra (NYSE:PEN) - Stock Analysis
This Simply Wall St analysis provides an overview of Penumbra (NYSE:PEN), a company specializing in medical devices for vascular and neurovascular diseases. The report highlights analyst consensus targeting a 9.1% undervaluation, a forecasted 17.2% annual earnings growth, and recent news including clinical trial results and executive stock sales. It also compares Penumbra to competitors and offers historical price performance data.
Penumbra Inc stock (US70975L1070): Why its neurovascular leadership matters more now for investors
Amidst economic headwinds in 2026, Penumbra Inc's strong position in the neurovascular and vascular treatment market makes its stock resilient. The company's focus on life-saving treatments for stroke and blood clot removal, technological edge, and strong financial health provide stability regardless of broader market fluctuations, making it an appealing option for investors looking for growth with stability in a diversified portfolio. Penumbra's continued innovation and international expansion further solidify its market position.
Penumbra Inc stock (US70975L1070): Why its neurovascular leadership matters more now for investors
Penumbra Inc, a medical device company specializing in neurovascular and vascular treatments, is positioned for resilience in 2026 despite economic headwinds like low consumer sentiment and inflation. The company's focus on essential, life-saving stroke and blood clot removal devices ensures steady demand regardless of economic cycles. Penumbra's strong balance sheet, technological leadership in thrombectomy, and expansion into international markets make it an attractive option for investors seeking stability and growth in a high-interest-rate environment.
Penumbra Presents STORM-PE 90-day Results at SIR
Penumbra announced the 90-day results from its STORM-PE randomized controlled trial at the SIR Annual Scientific Meeting. The study found that patients with acute intermediate-high risk pulmonary embolism treated with computer-assisted vacuum thrombectomy (CAVT) plus anticoagulation showed significantly greater functional improvement compared to those treated with anticoagulation alone. Key improvements included longer walking distances, a higher proportion achieving no physical limitations, and comparable safety rates between the two groups.
Study backs Penumbra computer-assisted thrombectomy
Penumbra announced 90-day results from its STORM-PE randomized trial, showing that its Lightning Flash computer-assisted vacuum thrombectomy (CAVT) system, combined with anticoagulation, led to greater functional improvement for patients with acute intermediate-high risk pulmonary embolism compared to anticoagulation alone. Patients experienced significantly longer walking distances and returned to pre-PE functional status with a comparable safety profile. The company also presented an interim analysis from its STRIKE-PE study, further supporting the long-term quality of life and functional outcomes from CAVT.
Penumbra trial shows improved outcomes for pulmonary embolism
Penumbra Inc. (NYSE:PEN) announced positive 90-day results from its STORM-PE trial, demonstrating that patients with acute intermediate-high risk pulmonary embolism treated with computer-assisted vacuum thrombectomy combined with anticoagulation showed greater functional improvement compared to anticoagulation alone. The company's stock has seen a 30% return over the past six months, reflecting strong market performance. These results come amidst recent news of Boston Scientific acquiring Penumbra, which has led to mixed analyst ratings.
New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients
Penumbra (NYSE: PEN) announced positive 90-day results from its STORM-PE randomized controlled trial, indicating that computer-assisted vacuum thrombectomy (CAVT) combined with anticoagulation led to significantly better functional outcomes for intermediate-high risk pulmonary embolism (PE) patients compared to anticoagulation alone. Patients treated with CAVT walked significantly further in a six-minute walk test and achieved higher rates of no physical limitation. The safety profile was comparable between both treatment arms, with no device-related mortality.
New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients
New data from the STORM-PE trial show that computer assisted vacuum thrombectomy (CAVT) with anticoagulation significantly improved functional outcomes at 90 days for patients with acute intermediate-high risk pulmonary embolism (PE) compared to anticoagulation alone. Patients treated with CAVT walked significantly further and a higher proportion achieved no physical limitations. This pivotal trial reinforces the benefits of endovascular therapy for PE and its potential to influence future clinical guidelines.
Baillie Gifford & Co. Sells 32,221 Shares of Penumbra, Inc. $PEN
Baillie Gifford & Co. reduced its stake in Penumbra, Inc. by 3.5% in the fourth quarter, selling 32,221 shares and retaining 876,325 shares valued at approximately $272.5 million. Penumbra experienced an EPS miss of -$0.37 against estimates of $1.12, but revenue surpassed expectations at $385.39 million, a 22.2% increase year-over-year. The stock currently holds a consensus "Hold" rating from analysts with an average price target of $361.69.
